NCT04625205CompletedPhase 1
An open-label Phase 1 study of NEO-PTC-01 in patients with advanced or metastatic melanoma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 18 Nov 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- First submitted
- 20 Nov 2023
- Start date
- 1 Dec 2020
- Lead sponsor
- Biontech US Inc.
- Diseases
- Melanoma
- NCT number
- NCT04625205
- EU CT number
- 2023-508524-35-00
- EudraCT number
- 2019-003908-13
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 72
- 3 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UZ Brussel Coordinator of this site? Confirm its status | Jette | Belgium | Completed |
| Vall D'hebron Institut De Recerca Coordinator of this site? Confirm its status | Barcelona | Spain | Completed |
| Netherlands Cancer Institute Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.